Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T Lymphocytes

NCT ID: NCT05792995

Last Updated: 2023-03-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-12-21
• Study Completion Date: 2023-03-01

Brief Summary

Providing more theoretical basis for the prediction of the efficacy of advanced NSCLC and helping select better advantaged population of NSCLC immunotherapy to maximize the benefits of patients By exploring the relationship between the changes of PD-1 expression in peripheral blood T lymphocytes and the clinical efficacy before and after the use of PD-1 / PD-L1 inhibitors.

Detailed Description

From the perspective of immunology, it is intended to explore whether the expression of PD-1 in peripheral blood T lymphocytes can be used as a reference index for selecting immune "+" therapy in patients with advanced HCC, and to clarify the relationship between the expression level of peripheral blood T lymphocytes and the survival data of patients receiving immune "+" therapy. And explore whether there is consistency between the expression level of PD-L1 and that of PD-L1 on patients. At the same time, to explore whether there is a correlation between the distribution of T cell subsets and the efficacy of immunotherapy, so as to provide a new theoretical basis for the clinical screening of the target population of immune "+" therapy and a new clinical screening index for the prognosis assessment of patients.

Conditions

Non-small Cell Lung Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Immunomonotherapy plus Chemotherapy plus Anti-angiogenesis Therapy

Any first-line treatment that includes immunotherapy.

Group Type: EXPERIMENTAL

Sindillimab

Intervention Type: DRUG

Any treatment regimen that includes immunotherapy.

Chemotherapy plus Immunomonotherapy

Any first-line treatment that includes immunotherapy.

Group Type: EXPERIMENTAL

Sindillimab

Intervention Type: DRUG

Any treatment regimen that includes immunotherapy.

Immunomonotherapy plus Anti-angiogenesis Therapy

Any first-line treatment that includes immunotherapy.

Group Type: EXPERIMENTAL

Sindillimab

Intervention Type: DRUG

Any treatment regimen that includes immunotherapy.

Immunomonotherapy

Any first-line treatment that includes immunotherapy.

Group Type: EXPERIMENTAL

Sindillimab

Intervention Type: DRUG

Any treatment regimen that includes immunotherapy.

Interventions

Sindillimab

Any treatment regimen that includes immunotherapy.

Intervention Type: DRUG

Other Intervention Names

Pembrolizumab; Nivolumab; Durvalumab

Eligibility Criteria

Inclusion Criteria

1. Volunteer to participate in clinical research; fully understand and know the research and sign informed consent.

2. Age ≥18 years, and ≤75years , either sex.

3. Eastern Collaborative Oncology Group Performance status (ECOG PS) 0 ,1 or 2.

4. Patients with NSCLC diagnosed by histopathology (according to the 8th edition of AJCC).

5. Initial diagnosis patients unable to perform surgery.

6. Normal hepatic function: total bilirubin≤1.5×normal upper limit (ULN); Alanine aminotransferase and Aspartate aminotransferase levels ≤2.5×ULN or ≤5×ULN if liver metastasis is present.

7. Normal renal function ：Creatinine ≤1.5×ULN or calculated creatinine clearance ≥45 mL/min (using Cockcroft/Gault formula to calculate ).

8. Normal hematological function：absolute neutrophil count ≥1.5×109/L, platelet count ≥70×109/L, hemoglobin≥80g/L [no blood transfusion or erythropoietin (EPO) within 7 days] Dependency].

9. Has a life expectancy of at ≥3 months.

10. EGFR and ALK were negative.

Exclusion Criteria

1. ECOG PS >2.

2. Patients who received radiotherapy, chemotherapy, monoclonal antibody and oral EGFR-TKI therapy within six months.

3. Patients who are receiving any other investigational agents within 30 days prior to entering the study.

4. History of other malignancies (except for cured cervical carcinoma in situ or skin basal cell carcinoma and other malignancies that have been cured for more than 5 years).

5. Have no measurable lesion as defined by RECIST 1.1.

6. Accompanied by other serious diseases, including but not limited to:

Uncontrollable congestive heart failure (NYHA grade Ⅲ or Ⅳ), unstable angina, poorly controlled arrhythmia, uncontrolled moderate or above hypertension (SBP > 160mmhg or DBP > 100mmhg) ; Severe active infection; Uncontrollable diabetes (refers to the high fluctuation of blood glucose, the impact on patients' life and the frequent occurrence of hypotension despite the standard insulin treatment and frequent blood glucose monitoring) ; Mental illness affecting informed consent and / or program compliance.

7. Those who are allergic to the drug or its components used in the program.

8. Pregnancy (confirmed by hCG test in blood or urine) or lactating women, or childbearing age subjects are unwilling or unable to take effective contraceptive measures (applicable to both male and female subjects) until at least 6 months after the last trial treatment.

9. Those who are not considered suitable for the study by the researchers.

10. Unwilling to participate in this study or unable to sign informed consent.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Xin-Hua Xu

OTHER

Sponsor Role: lead

Responsible Party

Xin-Hua Xu

professor

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Department of Medical Oncology, Central Hospital of Yichang City, the First Clinical Medical College of Three Gorges University

Yichang, Hubei, China

Countries

China

Other Identifiers

CTGU007

Identifier Type: -

Identifier Source: org_study_id